bioRxiv Science⌕ Search

Biology subjects

Horn, G.

Publications and source records attributed to Horn, G..

2 recordsLinked to original sources

Somatic hypermutation-mediated paratope flexibility improves the cross-reactivity of human malaria antibodies

The protective capacity of antibodies targeting circumsporozoite protein on sporozoites of the malaria parasite Plasmodium falciparum (PfCSP) is linked to high affinity and cross-reactivity with the PfCSP central repeat domain and N-terminal junction. However, the role of somatic hypermutation (SHM) in the development of such antibodies remains unclear. Here we define the contributions of SHM to the high affinity and strong repeat and N-junction cross-reactivity of the potent anti-PfCSP monoclonal antibody (mAb) 4493 and of similar antibodies with shared SHM and affinity maturation trajectories. Molecular dynamics simulations reveal that SHM reduces the flexibility of the unbound mAb 4493 but increases the flexibility of the antigen-bound complex, thereby lowering the entropic cost for antigen binding. Furthermore, we identify an inverse relation between antibody affinity and serum stability, which limits the protective capacity of these antibodies. Our study provides molecular level evidence for the different roles that the SHM process plays in increasing VH3-49+V{kappa}3-20 antibody affinity and cross-reactivity and demonstrates how antibody affinity maturation can negatively impact antibody stability and thereby function.

immunology↗

Multityrosine Kinase Inhibitors Alleviate Laser-Induced Choroidal Neovascularization in Non-Human Primates: A Novel Therapy for Diabetic Retinopathy and Age-Related Macular Degeneration

Age-related macular degeneration (AMD) and diabetic retinopathy (DR) are leading causes of vision impairment worldwide. Both conditions involve retinal neovascularization and choroidal neovascularization (CNV), which can lead to severe vision loss. Current treatment options have limitations, necessitating the development of safer and more effective therapies. This study investigated the efficacy of Cabozantinib (CBZ), a multi-tyrosine kinase inhibitor, in a non-human primate model of retinal neovascularization. Laser-induced CNV was assessed, and CBZ demonstrated effectiveness in reducing CNV leakage and lesion area without intraocular toxicity. The inhibition of MET and VEGFR2 activation, involved in angiogenesis, is believed to be the mechanism of action. The findings support CBZs potential as a novel therapeutic agent for AMD and DR. Further investigations and clinical trials are warranted to evaluate CBZs long-term safety and efficacy in humans, as well as explore its effect on other pathways involved in CNV. The study supports the growing evidence that multi-tyrosine kinase inhibitors, including CBZ and Axitinib, hold promise in the treatment of ocular neovascularization, particularly in conditions like AMD and DR.

molecular biology↗